SCHEMBL23218162

SCHEMBL23218162

CCOC(=O)Cc1ccc(F)cc1OCc1coc2ccc(-c3cccc(CNC(=O)OC(C)(C)C)c3)cc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.36
TP53 P04637 1/20 0.36
MAPK14 Q16539 4/20 0.34
CFD P00746 1/20 0.34
NR1H2 P55055 2/20 0.34
NR1H3 Q13133 2/20 0.34
BRD4 O60885 2/20 0.34
CREBBP Q92793 1/20 0.34
RXRA P19793 1/20 0.34
BCHE P06276 1/20 0.33
CNR2 P34972 1/20 0.33
CASP1 P29466 1/20 0.33
HDAC1 Q13547 1/20 0.33
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MAPT P10636 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852557 1.00 GRM2 (0.36) GRM2TP53MAPK14CFDNR1H2
SCHEMBL23218237 0.91 TP53 (0.36) TP53CFDNR1H2NR1H3BRD4
SCHEMBL29852677 0.91 TP53 (0.36) TP53CFDNR1H2NR1H3BRD4
SCHEMBL29853071 0.89 BRD4 (0.35) TP53CFDNR1H2NR1H3BRD4
SCHEMBL23218268 0.89 BRD4 (0.35) TP53CFDNR1H2NR1H3BRD4
SCHEMBL23219042 0.88 TP53 (0.36) GRM2TP53CFDBCHECNR2
SCHEMBL29852916 0.88 TP53 (0.36) GRM2TP53CFDBCHECNR2
SCHEMBL23218473 0.88 TP53 (0.35) TP53CFDBRD4CREBBPCASP1
SCHEMBL29852424 0.88 TP53 (0.35) TP53CFDBRD4CREBBPCASP1
SCHEMBL23218400 0.83 TP53 (0.42) TP53BRD4CREBBPCASP1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB GRM2 4638/4885TP53 3891/4885MAPK14 2565/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB GRM2 4857/4885TP53 3580/4885MAPK14 1962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.